bluebird bio, up on first day of trading, plans late-stage study this year
June 19, 2013 at 14:11 PM EDT
A Cambridge, Mass. biotech, bluebird bio, has plans to begin a late-stage trial this year of a potential drug to treat a rare, inherited disorder that affects male children...
